Verve Therapeutics, Inc. (VERV) News
Filter VERV News Items
VERV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VERV News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VERV News From Around the Web
Below are the latest news stories about VERVE THERAPEUTICS INC that investors may wish to consider to help them evaluate VERV as an investment opportunity.
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 11:15 a.m. PT in San Francisco. A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be ar |
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31, 2024, the company granted equity awards to one new employee, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employee received an aggregate of 5 |
Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In?We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Verve Therapeutics, Inc. (NASDAQ:VERV) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge […] |
Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where Verve Therapeutics, Inc. (NASDAQ:VERV) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or […] |
Verve Therapeutics Slides As Insider Purchases Lose Another US$65kInsiders who bought US$475.8k worth of Verve Therapeutics, Inc.'s ( NASDAQ:VERV ) stock at an average buy price of... |
Verve Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsVerve Therapeutics ( NASDAQ:VERV ) Third Quarter 2024 Results Key Financial Results Revenue: US$6.87m (up 120% from 3Q... |
Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue EstimatesVerve Therapeutics (VERV) delivered earnings and revenue surprises of 15.71% and 13.47%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Verve Therapeutics: Q3 Earnings SnapshotBOSTON (AP) — Verve Therapeutics Inc. VERV) on Tuesday reported a loss of $50.1 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of 59 cents. |
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial ResultsSeven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 First participant dosed in the Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3; Regulatory clearances in Australia, Canada, and the U.K. Cash, cash equivalents, and marketable securities of $539.9 million; cash runway through 2026 BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company develo |
State Street Corp's Strategic Acquisition in Verve TherapeuticsOverview of the Recent Transaction On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 903,809 shares of Verve Therapeutics Inc (NASDAQ:VERV), a pioneering genetic medicines company. This transaction, executed at a price of $4.84 per share, increased State Street Corp's total holdings in Verve Therapeutics to 4,253,217 shares. This move reflects a strategic positioning by the firm, aiming to capitalize on the evolving biotechnology sector. |